1. Home
  2. ALT vs DFDV Comparison

ALT vs DFDV Comparison

Compare ALT & DFDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • DFDV
  • Stock Information
  • Founded
  • ALT 1997
  • DFDV 2018
  • Country
  • ALT United States
  • DFDV United States
  • Employees
  • ALT N/A
  • DFDV N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • DFDV Finance: Consumer Services
  • Sector
  • ALT Health Care
  • DFDV Finance
  • Exchange
  • ALT Nasdaq
  • DFDV Nasdaq
  • Market Cap
  • ALT 292.0M
  • DFDV 330.2M
  • IPO Year
  • ALT N/A
  • DFDV N/A
  • Fundamental
  • Price
  • ALT $3.83
  • DFDV $16.02
  • Analyst Decision
  • ALT Strong Buy
  • DFDV Buy
  • Analyst Count
  • ALT 6
  • DFDV 1
  • Target Price
  • ALT $17.40
  • DFDV $45.00
  • AVG Volume (30 Days)
  • ALT 3.0M
  • DFDV 3.5M
  • Earning Date
  • ALT 08-12-2025
  • DFDV 08-12-2025
  • Dividend Yield
  • ALT N/A
  • DFDV N/A
  • EPS Growth
  • ALT N/A
  • DFDV N/A
  • EPS
  • ALT N/A
  • DFDV 1.17
  • Revenue
  • ALT $20,000.00
  • DFDV $3,520,660.00
  • Revenue This Year
  • ALT N/A
  • DFDV $70.03
  • Revenue Next Year
  • ALT $761,880.20
  • DFDV $142.86
  • P/E Ratio
  • ALT N/A
  • DFDV $13.67
  • Revenue Growth
  • ALT N/A
  • DFDV 97.13
  • 52 Week Low
  • ALT $2.90
  • DFDV $0.49
  • 52 Week High
  • ALT $11.16
  • DFDV $53.88
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • DFDV 46.25
  • Support Level
  • ALT $3.35
  • DFDV $15.23
  • Resistance Level
  • ALT $3.66
  • DFDV $20.30
  • Average True Range (ATR)
  • ALT 0.19
  • DFDV 2.30
  • MACD
  • ALT 0.07
  • DFDV 0.08
  • Stochastic Oscillator
  • ALT 86.18
  • DFDV 19.72

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About DFDV DeFi Development Corp. Common Stock

DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.

Share on Social Networks: